Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01498484 · ClinicalTrials.gov registry record · Phase 2
Therapeutic Effects of Epstein-Barr Virus Immune T-Lymphocytes Derived From a Normal HLA-Compatible Or Partially-Matched Third-Party Donor in the Treatment of EBV Lymphoproliferative Disorders and EBV-Associated Malignancies
A Phase 2 study, sponsored by Atara Biotherapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 87
- Enrollment target
NCT01498484 is a Phase 2 study that has completed, run by Atara Biotherapeutics. The registered enrollment target is 87 participants.
The verdict
NCT01498484, a Phase 2 study, has completed, sponsored by Atara Biotherapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 87 participants
- Enrollment target
Study Summary
This is a Phase II trial to evaluate the efficacy and safety of human leukocyte antigen (HLA) partially-matched third-party allogeneic Epstein-Barr virus cytotoxic T lymphocytes (EBV-CTLs) for the treatment of EBV-induced lymphomas and EBV-associated malignancies.
Interventions
- BIOLOGICAL EBV-specific T cells (EBV-CTLs)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 87 participants |
| Start Date | 2011-12 |
| Est. Completion | 2019-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01498484
The ClinicalTrials.gov registry entry for NCT01498484 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 87 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Atara Biotherapeutics, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which EBV-specific T cells (EBV-CTLs) is the first listed.
NCT01498484 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01498484 about?
NCT01498484 is a clinical study titled "Therapeutic Effects of Epstein-Barr Virus Immune T-Lymphocytes Derived From a Normal HLA-Compatible Or Partially-Matched Third-Party Donor in the Treatment of EBV Lymphoproliferative Disorders and EBV-Associated Malignancies". This is a Phase II trial to evaluate the efficacy and safety of human leukocyte antigen (HLA) partially-matched third-party allogeneic Epstein-Barr virus cytotoxic T lymphocytes (EBV-CTLs) for the treatment of EBV-induced lymphomas and EBV-associated malignancies.
What is the current status of trial NCT01498484?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 87 participants. The study started on 2011-12. Estimated completion is 2019-07.
What interventions are being tested in trial NCT01498484?
The interventions under investigation include: EBV-specific T cells (EBV-CTLs) (BIOLOGICAL).
Who is sponsoring clinical trial NCT01498484?
This trial is sponsored by Atara Biotherapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.